| 1 |
ION363 (ulefnersen) |
3 |
-
antisense oligonucleotide treatment for people carrying a mutation in FUS gene
- sites in CA, MD, MA, MO, NY, OH, UT
|
Ionis Pharmaceuticals, Inc. |
| 2 |
MN-166 (ibudilast) |
2/3 |
-
50% chance of placebo for 12 months followed by an open label extension for 6 months
- sites in CA, FL, GA, IN, MD, MN, NY, NC, PA, VA
|
MediciNova |
| 3 |
RAPA-501 |
2/3 |
-
no placebo
- autologous hybrid TREG/Th2 cells delivered intravenously
- site in MA
|
Rapa Therapeutics LLC |
4 | digoxin | 2 | | Massachusetts General Hospital |
| 5 |
ranolazine |
2 |
-
placebo controlled trial evaluating two doses of ranolazine
- sites in CA, FL, KS, MO, OH
|
Swathy Chandrashekhar, MD |
| 6 |
VHB937 |
2 |
-
33% chance of placebo for 40 weeks followed by an open label extension
- intravenous delivery of an antibody designed to activate TREM2 protein
- site in CA, FL, GA, KS, MA, NE, NY, OH, TE, TX
|
Novartis Pharmaceuticals |
| 7 |
AMT-162 |
1/2 |
-
no placebo
- one-time gene therapy for SOD1-related ALS
- up to five years of follow-up
- sites in CA, MA, NY
|
UniQure Biopharma B.V. |
| 8 |
istradefylline and acute intermittent hypoxia |
1/2 |
-
crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- site in FL
|
University of Florida |
| 9 | | 1 | - 25% chance of placebo
- antisense oligoneucleotide not limited to genetic ALS and designed to target calpain 2
- intrathecal delivery of up to 4 doses
- sites in CA, DC, FL, MA, TN
| Amylyx Pharmaceuticals Inc. |
10 | | 1 | - no placebo
- cells that produce GDNF (a neurotrophic factor) are surgically transplanted into motor cortex of brain
- site in CA
| Cedars-Sinai Medical Center |
| 11 |
prosetin |
1 |
-
placebo controlled trial lasting 14 days followed by long term open label extension
- oral drug designed to target MAP4 kinase
- site in MA
|
ProJenX |
12 | | 1 | | Johns Hopkins University |
13 | | N/A | - no placebo
- trial evaluates multi-site direct current stimulation
- site in MA
| PathMaker Neurosystems Inc. |
14 | | N/A | - 2-4 week run in period followed by 2 weeks of SCAP with or without hand exercises
- trial being conducted at Bronx Veterans Administration Medical Center
- site in NY
| VA Office of Research and Development |
| 15 |
RAPA-501 |
EAP |
-
Expanded Access Program for people that are not eligible for trials
- Autologous hybrid TREG/Th2 cells delivered intravenously
- sites in AZ, CA, GA, IA, MA, MN, NJ, OR
|
Rapa Therapeutics LLC |
| 16 |
MN-166 (ibudilast) |
EAP |
-
Expanded Access Program for people that are not eligible for trials
- Contact WideTrial to join interest list to participate and see additional contact information here
- sites in FL, AZ
|
Mayo Clinic |
17 | | EAP | - Expanded Access Program
- Contact Spinogenix for more information here
| Spinogenix, Inc. |